Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
AssigneeWyeth
InventorsAnnaliesa Sybil Anderson, Kathrin Ute Jansen, Mark Edward Ruppen, Justin Keith Moran, Susan Kay Hoiseth
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.
Claims2
A method of eliciting an immune response against Neisseria meningitidis serogroup B, subfamily B, in a mammal, comprising administering to the mammal an immunogenic composition comprising an immunologically effective amount of a first non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
- 19, wherein the first non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO:
- 19 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
Dependencies are inferred from the claim text.